Resapp Health Ltd
ASX:RAP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Resapp Health Ltd
Net Income (Common)
Resapp Health Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Resapp Health Ltd
ASX:RAP
|
Net Income (Common)
-AU$7.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-24%
|
|
|
Mach7 Technologies Ltd
ASX:M7T
|
Net Income (Common)
-AU$6.2m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
1%
|
|
|
4DMedical Ltd
ASX:4DX
|
Net Income (Common)
-AU$30.1m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
CogState Ltd
ASX:CGS
|
Net Income (Common)
$10.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pro Medicus Ltd
ASX:PME
|
Net Income (Common)
AU$115.2m
|
CAGR 3-Years
37%
|
CAGR 5-Years
38%
|
CAGR 10-Years
43%
|
|
|
A
|
Artrya Ltd
ASX:AYA
|
Net Income (Common)
-AU$16.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-65%
|
CAGR 10-Years
N/A
|
|
Resapp Health Ltd
Glance View
ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The company is headquartered in Brisbane, Queensland. The company went IPO on 2005-01-12. The Company’s digital healthcare solutions assists doctors and patients to diagnose and manage respiratory disease. The firm has developed a platform for diagnosing respiratory disease using the sound of a patient’s cough. The platform is based on sound alone and does not require physical contact with the patient. With smartphones integrating microphones, the platform can be delivered without the need for additional hardware. The firm has developed smartphone-based machine learning algorithms, which can identify exacerbations in patients with asthma or COPD. The company also has ongoing clinical programs investigating the use of these techniques to measure exacerbation severity and lung function. The firm has developed an obstructive sleep aponia screening test that uses overnight breathing and snoring sounds recorded on a smartphone placed on the bedside table.
See Also
What is Resapp Health Ltd's Net Income (Common)?
Net Income (Common)
-7.1m
AUD
Based on the financial report for Jun 30, 2022, Resapp Health Ltd's Net Income (Common) amounts to -7.1m AUD.
What is Resapp Health Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-24%
Over the last year, the Net Income (Common) growth was -5%. The average annual Net Income (Common) growth rates for Resapp Health Ltd have been -9% over the past three years , 7% over the past five years , and -24% over the past ten years .